The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Assessment of addiction severity among ritual users of ayahuasca.
Abstract
Ayahuasca is a psychoactive beverage used for magico-religious purposes in the Amazon. Recently, Brazilian syncretic churches have helped spread the ritual use of ayahuasca abroad. This trend has raised concerns that regular use of this N,N-dimethyltryptamine-containing tea may lead to the medical and psychosocial problems typically associated with drugs of abuse. Here we assess potential drug abuse-related problems in regular ayahuasca users. Addiction severity was assessed using the Addiction Severity Index (ASI), and history of alcohol and illicit drug use was recorded. In Study 1, jungle-based ayahuasca users (n=56) were compared vs. rural controls (n=56). In Study 2, urban-based ayahuasca users (n=71) were compared vs. urban controls (n=59). Follow-up studies were conducted 1 year later. In both studies, ayahuasca users showed significantly lower scores than controls on the ASI Alcohol Use, and Psychiatric Status subscales. The jungle-based ayahuasca users showed a significantly higher frequency of previous illicit drug use but this had ceased at the time of examination, except for cannabis. At follow-up, abstinence from illicit drug use was maintained in both groups except for cannabis in Study 1. However, differences on ASI scores were still significant in the jungle-based group but not in the urban group. Despite continuing ayahuasca use, a time-dependent worsening was only observed in one subscale (Family/Social relationships) in Study 2. Overall, the ritual use of ayahuasca, as assessed with the ASI in currently active users, does not appear to be associated with the deleterious psychosocial effects typically caused by other drugs of abuse.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ritual use of ayahuasca shows considerable differences to the traditional psychosocial harms of drug consumption (Fábregas et al., 2010).”
From The therapeutic potentials of Ayahuasca: possible effects against various diseases of civilization (2016) · cites this paper as Fábregas et al., 2010
Citations
Cites
The Fifth Edition of the Addiction Severity Index.
Mclellan, A., Kushner, H., Metzger, D., Peters, R., Smith, I. E., Grissom, G. R., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,280
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Camí, J., & Farré, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023160 · Cited by 477
The pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455
The Addiction Severity Index at 25: Origins, contributions, and transitions
McLellan, A. T., Cacciola, J. C., Alterman, A. I., Rikoon, S. H., & Carise, C. (2006) · The American Journal on Addictions · doi:10.1080/10550490500528316 · Cited by 450
Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049882 · Cited by 390
Self-citationHuman psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil.
GROB, C. S., McKENNA, D. J., CALLAWAY, J. C., BRITO, G. S., NEVES, E. S., OBERLAENDER, G., SAIDE, O. L., LABIGALINI, E., TACLA, C., MIRANDA, C. T., et al. (1996) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199602000-00004 · Cited by 338
McKenna, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.03.002 · Cited by 321
Vollenweider, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00108-0 · Cited by 305
Flesh of the Gods : The Ritual Use of Hallucinogens
Furst, P. T. (1972) · Cited by 258
Cited by
Sorted by citations
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506
Psychedelics as Medicines: An Emerging New Paradigm
Nichols, D. E., Johnson, M., & Nichols, C. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.557 · Cited by 397
The Addiction Potential of Hyperpalatable Foods
Gearhardt, A. N., Davis, C. A., Kuschner, R., & Brownell, K. D. (2011) · Current Drug Abuse Reviews · doi:10.2174/1874473711104030140 · Cited by 372
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347
Psychiatry & the psychedelic drugs. Past, present & future
Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.040 · Cited by 343
Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada
Thomas, G., Lucas, P., Capler, N., Tupper, K., & Martin, G. (2013) · Current Drug Abuse Reviews · doi:10.2174/15733998113099990003 · Cited by 330
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J. S., Salam, I., Neill, J. C., & Nutt, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 359
Bouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042421 · Cited by 313
Self-citationdos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306
Potential Therapeutic Effects of Psilocybin
Johnson, M. W., & Griffiths, R. R. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0542-y · Cited by 328
Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts
Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780612 · Cited by 285
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119845793 · Cited by 225
Neuropharmacology of N,N-dimethyltryptamine
Carbonaro, T. M., & Gatch, M. B. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.016 · Cited by 268
The therapeutic potentials of Ayahuasca: possible effects against various diseases of civilization
Frecska, E., Bokor, P., & Winkelman, M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00035 · Cited by 242
Ayahuasca: pharmacology, neuroscience and therapeutic potential
Domínguez-Clavé, E., Soler, J., Elices, M., Pascual, J. C., Álvarez, E., de la Fuente Revenga, M., Friedlander, P., Feilding, A., & Riba, J. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.03.002 · Cited by 226
Classic hallucinogens in the treatment of addictions
Bogenschutz, M. P., & Johnson, M. W. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.03.002 · Cited by 226
Bouso, J. C., Palhano-Fontes, F., Rodríguez-Fornells, A., Ribeiro, S., Sanches, R., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., & Riba, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.008 · Cited by 218
Self-citationSoler, J., Elices, M., Franquesa, A., Barker, S., Friedlander, P., Feilding, A., Pascual, J. C., & Riba, J. (2016) · Psychopharmacology · doi:10.1007/s00213-015-4162-0 · Cited by 209
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
Psychedelic medicine: a re-emerging therapeutic paradigm
Tupper, K. W., Wood, E., Yensen, R., & Johnson, M. W. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.141124 · Cited by 187
Hamill, J., Hallak, J. E. C., Dursun, S. M., & Baker, G. B. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180125095902 · Cited by 201
Morales-García, J. A., de la Fuente Revenga, M., Alonso-Gil, S., Rodríguez-Franco, M. I., Feilding, A., Perez-Castillo, A., & Riba, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-05407-9 · Cited by 175
SANTOS, R. G. D., Osório, F. D. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2015-1701 · Cited by 175
Loizaga-Velder, A. K., & Verres, R. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2013.873157 · Cited by 157
Garcia‐Romeu, A., Davis, A. K., Erowid, E., Erowid, F., Griffiths, R. R., & Johnson, M. W. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00955 · Cited by 171
Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT
Dakic, V., Minardi Nascimento, J., Costa Sartore, R., Maciel, R. D. M., de Araujo, D. B., Ribeiro, S., Martins-de-Souza, D., & Rehen, S. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-12779-5 · Cited by 134
Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment
Brierley, D. I., & Davidson, C. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.001 · Cited by 138
Autonomic, Neuroendocrine, and Immunological Effects of Ayahuasca
SANTOS, R. G. D., Valle, M., Bouso, J. C., Nomdedeu, J. F., Rodrı́guez-Espinosa, J., McIlhenny, E. H., Barker, S. A., Barbanoj, M. J., & Riba, J. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823607f6 · Cited by 143
Self-citationWinkelman, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107120011 · Cited by 126
dos Santos, R. G., Balthazar, F. M., Bouso, J. C., & Hallak, J. E. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116652578 · Cited by 125
Self-citationBogenschutz, M. P., & Pommy, J. M. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1376 · Cited by 130
Health status of ayahuasca users
Barbosa, P. C. R., Mizumoto, S., Bogenschutz, M. P., & Strassman, R. J. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1383 · Cited by 112
Self-citationKavenská, V., & Simonová, H. (2015) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1094590 · Cited by 108
Galvão, A. C. D. M., de Almeida, R. N., Silva, E. A. D. S., Freire, F. A. D. M., Palhano-Fontes, F., Onias, H., Arcoverde, E., Maia‐de‐Oliveira, J. P., de Araújo, D. B., Soares, B. L., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00185 · Cited by 110
Psychological and neuropsychological assessment of regular hoasca users
Barbosa, P. C. R., Strassman, R. J., da Silveira, D. X., Areco, K., Hoy, R., Pommy, J., Thoma, R., & Bogenschutz, M. (2016) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2016.09.003 · Cited by 105
Self-citationWINSTOCK, A. R., Kaar, S. J., & Borschmann, R. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113513852 · Cited by 104
Soler, J., Elices, M., Dominguez-Clavé, E., Pascual, J. C., Feilding, A., Navarro-Gil, M., García-Campayo, J., & Riba, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00224 · Cited by 102
Argento, E., Capler, R., Thomas, G., Lucas, P., & Tupper, K. W. (2019) · Drug and Alcohol Review · doi:10.1111/dar.12985 · Cited by 102
Psychedelic therapy in the treatment of addiction: the past, present and future
Zafar, R. R., Siegel, M., Harding, R., Barba, T., Agnorelli, C., Suseelan, S., Roseman, L., Wall, M. B., Nutt, D., & Erritzøe, D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1183740 · Cited by 113
Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism
Bogenschutz, M. P., & Forcehimes, A. A. (2016) · Journal of Humanistic Psychology · doi:10.1177/0022167816673493 · Cited by 102
Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca
Barbosa, P. C. R., Tófoli, L. F., Bogenschutz, M. P., Hoy, R. V., Berro, L. F., Marinho, E. A. V., Areco, K. C. N., & Winkelman, M. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00136 · Cited by 97
Self-citationNunes, A. A., SANTOS, R. G. D., Osório, F. D. L., Sanches, R. F., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2016.1188225 · Cited by 95
Oliveira-Lima, A. J., Santos, R., Hollais, A. W., Gerardi-Junior, C. A., Baldaia, M. A., Wuo-Silva, R., Yokoyama, T. S., Costa, J. L., Malpezzi-Marinho, E. L. A., Ribeiro-Barbosa, P. C., et al. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.01.032 · Cited by 91
Safety and Side Effects of Ayahuasca in Humans—An Overview Focusing on Developmental Toxicology
SANTOS, R. G. D. (2013) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2013.763564 · Cited by 94
Therapeutic Applications of Classic Hallucinogens
Bogenschutz, M. P., & Ross, S. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_464 · Cited by 92
Domínguez‐Clavé, E., Soler, J., Pascual, J. C., Elices, M., Franquesa, A., Valle, M., Álvarez, E., & Riba, J. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5085-3 · Cited by 86
Kozłowska, U., Nichols, C. D., Wiatr, K., & Figiel, M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15509 · Cited by 86
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 92
Lawn, W., Hallak, J. E. C., Crippa, J. A. S., SANTOS, R. G. D., Porffy, L., Barratt, M. J., Ferris, J., WINSTOCK, A. R., & Morgan, C. J. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-14700-6 · Cited by 83
Ona, G., Kohek, M., Massaguer, T., Gomariz, A., Jiménez, D. F., Dos Santos, R. G., Hallak, J. E. C., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1567961 · Cited by 76
Self-citationTherapeutic potential of ayahuasca in grief: a prospective, observational study
González, D., Cantillo, J., Pérez, I., Farré, M., Feilding, A., Obiols, J. E., & Bouso, J. C. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05446-2 · Cited by 75
Self-citationRuffell, S., Netzband, N., Tsang, W., Davies, M., Inserra, A., Butler, M., Rucker, J., Tófoli, L. F., Dempster, E. L., Young, A. H., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.687615 · Cited by 74
Berlowitz, I., Walt, H., Ghasarian, C., Mendive, F., & Martin-Soelch, C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1607956 · Cited by 72
Walsh, Z., & Thiessen, M. S. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1474088 · Cited by 58
SANTOS, R. G. D., Bouso, J. C., Rocha, J. M., Rossi, G. N., & Hallak, J. E. C. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s300656 · Cited by 73
Self-citationMendes, F. R., Costa, C. D. S., Wiltenburg, V. D., Morales-Lima, G., Fernandes, J. A. B., & Filev, R. (2022) · Addiction Neuroscience · doi:10.1016/j.addicn.2022.100025 · Cited by 67
Modulatory effects of ayahuasca on personality structure in a traditional framework
Netzband, N., Ruffell, S., Linton, S., Tsang, W., & Wolff, T. J. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05601-0 · Cited by 56
Methodology for determining major constituents of ayahuasca and their metabolites in blood
McIlhenny, E. H., Riba, J., Barbanoj, M. J., Strassman, R. J., & Barker, S. A. (2011) · Biomedical Chromatography · doi:10.1002/bmc.1657 · Cited by 59
Self-citationLuoma, J. B., Sabucedo, P., Eriksson, J., Gates, N., & Pilecki, B. C. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.10.003 · Cited by 56
Ayahuasca: Uses, Phytochemical and Biological Activities
Estrella-Parra, E. A., Almanza-Pérez, J. C., & Alarcón-Aguilar, F. J. (2019) · Natural Products and Bioprospecting · doi:10.1007/s13659-019-0210-5 · Cited by 61
Perkins, D., Pagni, B. A., Sarris, J. J., Barbosa, P. C. R., & Chenhall, R. D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.884703 · Cited by 63
Self-citationPerkins, D., Opaleye, E. S., Šimonová, H., Bouso, J. C., Tófoli, L. F., Coelho, N. L. G., Schubert, V., & Sarris, J. J. (2021) · Drug and Alcohol Review · doi:10.1111/dar.13348 · Cited by 54
Self-citationSerotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies
Ross, S. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.04.002 · Cited by 54
Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies
Calleja‐Conde, J., Morales-Garcia, J. A., Echeverry‐Alzate, V., Bühler, K., Giné, E., & López‐Moreno, J. A. (2022) · Addiction Biology · doi:10.1111/adb.13229 · Cited by 58
Agin-Liebes, G., Nielson, E. M., Zingman, M., Kim, K., Haas, A., Owens, L. T., Rogers, U. A., & Bogenschutz, M. P. (2023) · Psychology of Addictive Behaviors · doi:10.1037/adb0000935 · Cited by 60
Lanaro, R., Calemi, D. B. D. A., Togni, L. R., Costa, J. L., Yonamine, M., Cazenave, S. O. S., & Linardi, A. (2015) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1013202 · Cited by 52
Cata-Preta, E. G., Serra, Y. A., Moreira-Junior, E. D. C., Reis, H. S., Kisaki, N. D., Libarino-Santos, M., Silva, R. R. R., Barros-Santos, T., Santos, L. C., Barbosa, P. C. R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00561 · Cited by 53
Self-citationYaden, D. B., Berghella, A. P., Regier, P. S., Garcia‐Romeu, A., Johnson, M. W., & Hendricks, P. S. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103380 · Cited by 55
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism
Mitchell, J., & Anderson, B. T. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01656-7 · Cited by 55
Ayahuasca: A review of historical, pharmacological, and therapeutic aspects
Ruffell, S., Crosland‐Wood, M., Palmer, R., Netzband, N., Tsang, W., Weiss, B., Gandy, S., Cowley‐Court, T., Halman, A., McHerron, D., et al. (2023) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.146 · Cited by 61
Ayahuasca’s Antidepressant Effects Covary with Behavioral Activation as Well as Mindfulness
Mian, M. N., Altman, B. R., & Earleywine, M. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1674428 · Cited by 47
Acute effects of ayahuasca in a juvenile non-human primate model of depression
da Silva, F. S., Silva, E. A. D. S., de Sousa, G. M., Maia‐de‐Oliveira, J. P., Soares-Rachetti, V. D. P., de Araújo, D. B., de Sousa, M. B. C., Soares, B. L., Hallak, J. E. C., & Coelho, N. L. G. (2018) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2018-0140 · Cited by 55
Psychedelics and potential benefits in “healthy normals”: A review of the literature
Gandy, S. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.029 · Cited by 52
Rodrigues, L. S., Rossi, G. N., Rocha, J. M., Osório, F. D. L., Bouso, J. C., Hallak, J. E. C., & SANTOS, R. G. D. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01267-7 · Cited by 47
Self-citationAyahuasca's therapeutic potential: What we know – and what not
Maia, L. O., Daldegan‐Bueno, D., Wießner, I., de Araújo, D. B., & Tófoli, L. F. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.10.008 · Cited by 54
Harmine augments electrically evoked dopamine efflux in the nucleus accumbens shell
Brierley, D., & Davidson, C. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112463125 · Cited by 44
Forbidden Therapies: Santo Daime, Ayahuasca, and the Prohibition of Entheogens in Western Society
Blainey, M. G. (2014) · Journal of Religion and Health · doi:10.1007/s10943-014-9826-2 · Cited by 45
N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine
James, E., Keppler, J., Robertshaw, T. L., & Sessa, B. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2835 · Cited by 50
The Shipibo ceremonial use of ayahuasca to promote well-being: An observational study
Gonzalez, D., Cantillo, J., Perez, I., Carvalho, M., Aronovich, A., Farre, M., Feilding, A., Obiols, J. E., & Bouso, J. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623923 · Cited by 40
Self-citationKoslowski, M., Johnson, M. W., Gründer, G., & Betzler, F. (2021) · Current Addiction Reports · doi:10.1007/s40429-021-00401-8 · Cited by 42
Apud, I., & Romaní, O. (2016) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2016.07.011 · Cited by 40
Behavioral Changes Over Time Following Ayahuasca Exposure in Zebrafish
Savoldi, R., Polari, D., Pinheiro‐da‐Silva, J., Silva, P. F., Soares, B. L., Yonamine, M., Freire, F. A. D. M., & Luchiari, A. C. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00139 · Cited by 39
Ayahuasca and the Treatment of Drug Addiction
Bouso, J. C., & Riba, J. (2013) · Springer eBooks · doi:10.1007/978-3-642-40426-9_6 · Cited by 42
Self-citationBarsuglia, J. P., Polanco, M., Palmer, R., Malcolm, B. J., Kelmendi, B., & Calvey, T. (2018) · Progress in Brain Research · doi:10.1016/bs.pbr.2018.08.002 · Cited by 38
Fernández, X., dos Santos, R. G., Cutchet, M., Fondevila, S., González, D., Alcázar, M. Á., Riba, J., Bouso, J. C., & María Fábregas, J. (2014) · The Therapeutic Use of Ayahuasca · doi:10.1007/978-3-642-40426-9_11 · Cited by 36
Self-citationThe therapeutic potentials of Ayahuasca in the treatment of depression
Palhano-Fontes, F., Alchieri, J. C., Oliveira, J. P. M., Soares, B. L., Hallak, J. E. C., Galvao-Coelho, N., & de Araujo, D. B. (2014) · The Therapeutic Use of Ayahuasca · doi:10.1007/978-3-642-40426-9_2 · Cited by 36
Aicher, H. D., Mueller, M. J., Dornbierer, D. A., Suay, D., Elsner, C., Wicki, I., Meling, D., Caflisch, L., Hempe, A., Steinhart, C., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1302559 · Cited by 33
Egger, K., Aicher, H., Cumming, P. D., & Scheidegger, M. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05353-6 · Cited by 37
Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation
Johnson, M. W. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_327 · Cited by 37
Spirituality, drugs, and tourism: tourists’ and shamans’ experiences of ayahuasca in Iquitos, Peru
Prayag, G., Mura, P., Hall, C. M., & Fontaine, J. (2016) · Tourism Recreation Research · doi:10.1080/02508281.2016.1192237 · Cited by 33
Argento, E., Socias, M. E., Hayashi, K., Choi, J., Mackay, L., Christie, D., Milloy, M., & DeBeck, K. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103518 · Cited by 35
Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine
O’Shaughnessy, D. M., Berlowitz, I., Rodd, R., Sarnyai, Z., & Quirk, F. H. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320986634 · Cited by 32
Kaasik, H., & Kreegipuu, K. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1748773 · Cited by 37
Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil
Daldegan‐Bueno, D., Maia, L. O., Massarentti, C. M., & Tófoli, L. F. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06063-2 · Cited by 34
New insights into the chemical composition of Ayahuasca
Rodríguez, L., López, A., Moyna, G., Seoane, G. A., Davyt, D., Vázquez, Á., Hernández, G., & Carrera, I. (2022) · ACS Omega · doi:10.1021/acsomega.2c00795 · Cited by 30
Socha, D. M., Sykutera, M., Reinhard, J., & Perea, R. C. (2022) · Journal of Archaeological Science Reports · doi:10.1016/j.jasrep.2022.103415 · Cited by 30
Ayahuasca and cancer treatment
Schenberg, E. E. (2013) · SAGE Open Medicine · doi:10.1177/2050312113508389 · Cited by 33
Dimethyltryptamine: Endogenous Role and Therapeutic Potential
Rodrigues, A. V., Almeida, F., & Vieira‐Coelho, M. A. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1602291 · Cited by 34
Anderson, B. T., Labate, B. C., Meyer, M. J., Tupper, K. W., Barbosa, P. C. R., Grob, C. S., Dawson, A., & McKenna, D. J. (2012) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2012.02.007 · Cited by 32
Self-citation
Metadata
- Authors
- Fábregas, J. M., González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P. C. R., Alcázar-Córcoles, M. Á., Barbanoj, M. J., Riba, J., & Bouso, J. C.
- Affiliations
- Universidad Complutense de Madrid (ES)
- Universidade Estadual de Santa Cruz (BR)
- Universitat Autònoma de Barcelona (ES)
- Hospital de Sant Pau (ES)
- Corresponding author
- Bouso, José Carlos
- ORCID
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2010-10
- Volume
- 111
- Issue
- 3
- Pages
- 257-261
- ISSN
- 0376-8716 (ISSN-L)
- OpenAlex
- W2116852450
- Cited by
- 227
- References
- 25
- Citations by year
- 2026: 7 · 2025: 16 · 2024: 18 · 2023: 16 · 2022: 25 · 2021: 28 · 2020: 11 · 2019: 15 · 2018: 17 · 2017: 11 · 2016: 15 · 2015: 11 · 2014: 7 · 2013: 11 · 2012: 13
- FWCI
- 9.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug and Alcohol Dependence (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- ayahuasca, ritual drug use, addiction severity, N,N-dimethyltryptamine, illicit drug use, cannabis use, alcohol consumption, psychosocial impact, family and social relationships, Addiction Severity Index
- MeSH terms
- Adult, Brazil, Ceremonial Behavior, Female, Follow-Up Studies, Humans, Male, Middle Aged, Severity of Illness Index, Illicit Drugs, Behavior, Addictive, Substance-Related Disorders, Banisteriopsis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review